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valid, and reflect clinically meaningful changes. There is a lack of instruments that meet all these
criteria. In the Capturing Changes in Cognition (Catch-Cog) study, we seek to correct these defi-
ciencies through the development and validation of a composite measure combining cognition and
function: the cognitive-functional composite (CFC). We expect that the CFC is able to detect clini-
cally relevant changes over time in early dementia stages of AD.
Methods/Design: We will include patients (n 5 350) with mild cognitive impairment or mild de-
mentia due to AD from memory clinics in the Netherlands and the United Kingdom. We will include
cognitively healthy volunteers (n5 30) as a control group. The CFC is based on the “cognitive com-
posite” and the Amsterdam instrumental activities of daily living questionnaire. We will investigate
test–retest reliability with baseline and 2- to 3-week follow-up assessments (n 5 50 patients and
n 5 30 healthy controls). We will involve experts and participants to evaluate the initial feasibility
and refine the CFC if needed. Subsequently, wewill perform a longitudinal construct validation study
in a prospective cohort (n 5 300) with baseline, 3-, 6-, and 12-month follow-up assessments. The
main outcome is cognitive and functional progression measured by the CFC. Reference measures
for progression include traditional cognitive and functional tests, disease burden measures, and brain
imaging methods. Using linear mixed modeling, we will investigate longitudinal changes on the CFC
and relate these to the reference measures. Using linear regression analyses, we will evaluate the in-
fluence of possible confounders such as age, gender, and education on the CFC.
Discussion: By performing an independent longitudinal construct validation, the Catch-Cog study of
the novel CFC will contribute to the improvement of disease monitoring and treatment evaluation in
early dementia stages of AD.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Cognition; Composite measure; Daily function; Longitudinal construct validation; Mildcognitive impairment; Prospective cohortthor. Tel.: 131 20 4448527.
utten@vumc.nl
16/j.trci.2017.01.004
he Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
commons.org/licenses/by-nc-nd/4.0/).
R.J. Jutten et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 130-138 1311. Background
Assessing cognition in Alzheimer’s disease (AD) is
essential for establishing diagnosis, monitoring progression,
and evaluating treatments [1,2]. Commonly used cognitive
tests have shown adequate quality for diagnostic use [3,4].
However, the quality of these tests for the measurement of
changes over time remains questionable [5].
One limitation is the duration of cognitive assessment,
which can take up to several hours. This can be burdensome
for patients and result in fatigue and loss of concentration.
These factors add to measurement error and may be a reason
for patients to abort the testing procedure [6]. A European
Task Force suggested that measuring progression in mild
AD should focus on the domains that are vulnerable for
decline, specifically episodic memory (EM), working mem-
ory (WM), and executive functioning (EF) [7]. A benefit of
this specificity is more concise testing.
Avariety of tests are available for the previously specified
domains [8]. However, most of these are unable to detect
changes over time in mild cognitive impairment (MCI) and
mild AD [9]. For example, mixed results are found for the
cognitive part of the Alzheimer’s Disease Assessment Scale
(ADAS-Cog), a test battery frequently used to evaluate ther-
apies in AD [10]. Previous studies have demonstrated that
most ADAS-Cog subtests suffer from either floor or ceiling
effects in MCI and mild AD, which strongly limits their
sensitivity to changes over time [11–13]. However, there is
also evidence that some parts show good responsiveness in
these disease stages [14,15]. Potentially sensitive tests for
EF originate from the Neuropsychological Test Battery
(NTB) [16]. Based on existing data on the ADAS-Cog and
NTB, Harrison et al. selected three EM tests and two EF tests
with a total administration time of 20 minutes. First results
showed this “cognitive composite” (CC) to be a concise
and reliable measure in mild AD [17].
Although cognitive performance is an important predic-
tor of everyday life performance, test scores only explain
part of the variance in functional status, which limits their
clinical relevance [18]. Informant reports measuring “instru-
mental activities of daily living” (IADL) may complement
cognitive assessments to provide a clinically meaningful
change [19]. IADL are cognitively complex everyday activ-
ities, such as cooking and managing finances [20]. Unfortu-
nately, the psychometric quality of most existing IADL
instruments is questionable or unknown [21,22]. Recent
promising developments include the Amsterdam IADL
Questionnaire (A-IADL-Q): an informant-based measure
with good psychometric properties regarding reliability, val-
idity, responsiveness, and diagnostic accuracy in early de-
mentia [23–26]. The A-IADL-Q is now incorporated in the
European Prevention of Alzheimer’s Dementia study given
its potential capacity to measure functional changes in
preclinical and prodromal AD [27].
Combining sensitive cognitive and functional tests into a
single composite measure may yield a useful tool to detectclinically relevant changes over time in MCI and mild AD
[28]. This is highly relevant for symptomatic and disease-
modifying trials, in which treatments are tested that aim to
improve cognition and function [7]. Previous studies have
proposed composite measures as endpoints for longitudinal
changes. Most of these involve cognitive tests only [29–
31] or address global function without focusing on specific
activities of daily living [32], which hampers their clinical
relevance. Furthermore, they are designed using retrospec-
tive data sets and thus need further validation in independent
cohorts. An independently validated measure to detect clin-
ically meaningful changes over time in MCI and mild AD is
thus still lacking. Therefore, the “Capturing Changes in
Cognition” (Catch-Cog) study has been designed. We aim
to develop and validate a short composite measure
combining cognition and function: the cognitive-functional
composite (CFC). The CFC is based on preparatory work
on the CC and A-IADL-Q. We expect that the CFC is able
to detect changes over time in MCI and mild AD and that
these changes relate to clinical and biological measures
associated with disease progression.2. Methods and design
2.1. Study participants
Wewill include patients (n5 350) with MCI or mild AD.
They will be recruited via outpatient memory clinics from
(1) the VU University Medical Center (VUmc) Alzheimer
Center, Amsterdam, The Netherlands (n5 140); (2) the Alz-
heimer Center Rotterdam, The Netherlands (n5 50); (3) the
University Medical Center Groningen (UMCG), The
Netherlands (n 5 60); and (4) the Brain Health Clinic at
the University of Edinburgh, United Kingdom (n 5 100).
Before inclusion, participants have undergone a dementia
assessment in their center, including medical history, neuro-
logical and neuropsychological examination, and brain im-
aging. Diagnoses are made according to the National
Institution on Aging criteria [1,33], in a multidisciplinary
diagnostic meeting including at least a neurologist or
psychiatrist with neuropsychology input. To ensure mild
AD, we will include people with a Mini–Mental State
Examination (MMSE) score 18 [34]. Other inclusion
criteria include age 50; sufficient proficiency of the study
language; and availability of a study partner. Exclusion
criteria address potential confounders for cognitive and
functional decline, specifically presence of another signifi-
cant neurological or psychiatric disorder; Geriatric Depres-
sion Scale score 6 [35]; and current abuse of alcohol or
drugs. We will also exclude people who participate in a clin-
ical trial within our follow-up time frame, to avoid potential
practice effects due to repeated cognitive testing.
In the VUmc Alzheimer Center, we will additionally
include cognitively healthy participants (n5 30) as a control
group. They will be recruited from an existing database con-
taining healthy volunteers. Before enrollment, all
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to ensure cognitive performance within the range of age- and
education-adjusted norms; age 50; and availability of a
study partner. The Medical-Ethical Committee of the
VUmc approved the study for all Dutch centers. The South
East Scotland Research Ethic Committee approved the study
for the UK site.2.2. Study design
We will use a mixed-methods design to develop the
CFC (see Fig. 1). Based on preparatory work on the CC
and A-IADL-Q, we will design a first version of the
CFC in our working group (consisting of R.J.J., J.H.,
F.J., A.A., C.W.R., P.S., and S.A.M.S.). We will pilot test
this version in patients (n 5 50) and healthy controls
(n 5 30) to investigate test–retest reliability (baseline
and 2- to 3-week follow-up assessments) (A). During the
test–retest study, we will evaluate the initial feasibility by
interviewing a subsample of patients (n 5 15) (B). Addi-
tionally, we will investigate experts’ needs and wishes
for a measure of clinical progression, using an online sur-
vey that we will distribute among various professional de-Input 
experts 
(C&D)
Interview 
patients (B)
Final version CFC
Preparatory work 
CC & A-IADL-Q
Test-retest 
study 
(A)
Fig. 1. Development procedure of the cognitive-functional composite. The
first version of the CFC is based on the CC and A-IADL-Q. Output from the
test–retest study (A), participant interviews (B), expert survey (C), and advi-
sory board (D) will be integrated to determine the final version of the CFC.
Abbreviations: A-IADL-Q, Amsterdam IADL questionnaire; CC, cognitive
composite; CFC, cognitive-functional composite.mentia networks (C). Furthermore, we will involve an
advisory board consisting of health care professionals
and potential future end users of the CFC (D). We will
use input from these experts to establish content validity.
Finally, output from all four steps (A–D) will be integrated,
discussed in the working group, and used to determine the
final version of the CFC.
Subsequently, we will perform a longitudinal con-
struct validation study in a prospective cohort with baseline,
3-, 6-, and 12-month follow-up assessments (n 5 300). A
construct validation approach is chosen [36] because a
gold standard for “clinical progression” is lacking. That is,
we will include measures that assess different aspects of dis-
ease progression, such as subjective perceived decline, dis-
ease burden, and brain atrophy. We will also include
traditional cognitive and functional tests to compare the
CFC with. As shown in Fig. 2, the CFC and reference test
of cognition, function, and subjective perceived decline
will be assessed at each time point. Disease burden measures
will be repeated at 6- and 12-month follow-up. Apathy eval-
uation and brain imaging will be repeated at 12-month
follow-up. For a subgroup (n 5 100), the 3-month follow-
up will be discarded, to examine potential practice effects
that may result from repeated testing within the 3-month
time frame [37]. We will compare their trajectory of decline
with the subgroup for which the 3-month assessment was
retained.2.3. Outcome parameters
Main outcome parameter is progression in cognition
and function measured by the CFC. Reference measures
consist of traditional cognitive and functional tests, subjec-
tive perceived decline, disease burden measures, and brain
imaging.
2.3.1. The cognitive-functional composite
The cognitive part of the CFC is based on the CC, which
includes (1) ADAS-Cog Word Recognition; (2) ADAS-Cog
Orientation; (3) ADAS-Cog Word Recall; (4) Controlled
Oral Word Association Test; and (5) Category Fluency
Test (see Table 1). Previous work on the CC demonstrated
good internal consistency (Cronbach’s alpha 5 0.80) and
test–retest reliability at 4 (r 5 0.89), 12 (r 5 0.85), 18
(r 5 0.84), and 24 weeks (r 5 0.84) in mild AD [17]. To
cover the EF and WM domains more broadly, we comple-
mented the CC with the Digit Span Backward Task. This
test has also been a feature of the NTB [38]. In addition,
we included the Digit Symbol Substitution Test. This mea-
sure has performed as being sensitive to changes in recently
reported clinical drug trials of cognitively enhancing com-
pounds [39]. It has also been listed in recent guidance for de-
mentia drug development as a measure of timed EF, as well
as having been selected as the EF component of recently pro-
posed theoretically and empirically driven composite mea-
sures for preclinical AD [30,40].
Baseline
• CFC
• Reference tests:
- cognition*
- function†
- perceived decline‡
- disease burden§ 
- apathy evaluation¶
- brain imaging#
3 months 6 months 12 months
• CFC
• Reference tests:
- cognition*
- function†
- perceived decline‡
• CFC
• Reference tests:
- cognition*
- function†
- perceived decline‡
- disease burden§
• CFC
• Reference tests:
- cognition*
- function†
- perceived decline‡
- disease burden§ 
- apathy evaluation¶
- brain imaging#
Fig. 2. Schematic overview of the longitudinal construct validation study design. Reference tests including corresponding symbols: *Mini–mental State Ex-
amination, Clinical dementia rating scale, and Alzheimer’s Disease Assessment Scale–Cognitive subscale. yAlzheimer’s Disease Cooperative Study–Activities
of Daily Living inventory and Cognitive Function Index. zVisual analogue scales for subjective perceived decline in cognitive functioning, everyday func-
tioning, and social functioning. xZarit Burden Inventory-12 item version and Quality of Life in Alzheimer’s disease scale. {Apathy Evaluation Scale. #MRI
scan including at least 3D-weighted T1, T2 and 3D FLAIR imaging. Abbreviations: CFC, cognitive functional composite; MRI, magnetic resonance imaging;
FLAIR, fluid-attenuated inversion recovery.
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Q: an informant-based, computerized questionnaire
covering a broad range of IADL activities. For each activity,
difficulty in performance is rated on a five-point Likert scale
(ranging from “no difficulty in performing this task” to “no
longer able to perform this task”). Good psychometric prop-
erties have been demonstrated previously: factor analysis
supported unidimensionality, high internal consistency (reli-
ability coefficient: 0.97) and good test–retest reliability (k
values. 0.60 for 87.9% of the items) [23]. A construct vali-
dation study showed in accordance with prior hypotheses
medium to high correlations with traditional measures of
everyday and cognitive functioning, suggesting good
construct validity [24]. Furthermore, a recent longitudinal
validation study demonstrated that the A-IADL-Q was
able to measure changes in IADL functioning, in particular
in patients with dementia [26]. In the present study, we
will use a short version of the A-IADL-Qwhich was recently
developed and showed good psychometric quality [41].
The ultimate CFC score will be based on the combination
of both components. We will explore both theoretically or
empirically driven weighting of the subcomponents, toTable 1
Overview of the cognitive-functional composite
Content aspects Ad
Test Domain Co
Cognitive part
ADAS-Cog Word Recognition EM Par
ADAS-Cog Orientation EM
ADAS-Cog Word Recall EM
Digit Span Backward Task WM
COWAT EF
CFT EF
DSST EF
Functional part
A-IADL-Q-SV IADL Stu
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive s
Oral Word Association Test; CFT, Category Fluency Test; EF, executive functionin
Questionnaire–short version; IADL, instrumental activities of daily living.determine what provides most optimal weighting for the
score (e.g., use equal weights for all components or differen-
tial weights for different components).
2.3.2. Cognitive reference tests
Reference measures for cognition include the MMSE,
Clinical Dementia Rating (CDR) scale, and the ADAS-
Cog-13. These tests are widely used in both clinical practice
and research. The MMSE was originally designed as
screening test for the grading of dementia severity [34]. It
consists of 30 items all briefly screening different aspects
of cognition (e.g., memory, attention and visuospatial skills).
Total scores range from 0 to 30, with lower scores reflecting
more severe impairment.
The CDR was developed for the staging of dementia
severity [42]. Based on an interview with both the study part-
ner and participant, the clinician rates the participant’s
cognitive and functional performance in six areas: memory,
orientation, judgment and problem solving, community af-
fairs, home and hobbies, and personal care. Each area is
rated as 0 (“healthy”), 0.5 (“questionable dementia”), 1
(“mild dementia”), 2 (“moderate dementia”), or 3 (“severeministration aspects
mpleted by Modality Duration
ticipant On paper 20–25 minutes
dy partner Electronical 10–15 minutes
ubscale; EM, episodic memory;WM,workingmemory; COWAT, Controlled
g; DSST, Digit Symbol Substitution Test; A-IADL-Q-SV, Amsterdam IADL
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score ranging from 0 to 18, with higher scores reflecting
more severe dementia [43].
The ADAS-Cog-13 is a cognitive test battery that mea-
sures cognitive performance by combining ratings of 13 sub-
tests (e.g., constructional praxis, object, and finger naming)
[10]. Because three ADAS-Cog-13 subtests are incorporated
in the CFC, we will assess the remaining subtests after as-
sessing the CFC. Performance on the CFC ADAS-Cog tests
will be included in the scoring. Total scores range from 0 to
85, with higher scores indicating more severe impairment.
2.3.3. Functional reference tests
Reference measures for daily function include the Alz-
heimer’s Disease Cooperative Study—Activities of Daily
Living inventory (ADCS-ADL) and the Cognitive Function
Instrument (CFI). The ADCS-ADL was designed to assess
functional abilities affected in AD and is still widely used
in clinical trials [44]. It was developed for a mild-to-
moderate AD population and contains both basic and instru-
mental activities. For 23 different activities, the levels of
performance and independency during the past 4 weeks
are rated by the study partner. Total scores range from
0 (nonperformance or need for extensive help) to 78 (inde-
pendent performance).
The CFI was originally developed to detect early clinical
changes in individuals at the preclinical stages of AD [45].
The questionnaire includes 14 items that ask about decline
in day-to-day cognitive and functional abilities, compared
with 1 year ago. Response options include “yes” (0), “no”
(1), or “maybe” (0.5), with total scores ranging from 0 to
14. There is a version for the participant and for the study
partner with the same questions. In the present study, we
will only include the study partner version, as patients are
already in the clinical phase of the disease and insight in
functioning is likely to be comprised.
2.3.4. Subjective perceived decline
Subjective perceived decline will be measured using vi-
sual analogue scales (VAS), ranging from 0 (“no decline”)
to 100 (“severe decline”). Participants and study partners
are independently asked to rate severity of decline in (1)
cognitive functioning; (2) everyday functioning; and (3) so-
cial functioning, compared to 3 months ago.
2.3.5. Disease burden measures
Caregiver burden will be measured using the short
version of the Zarit Burden Inventory (ZBI-12). The ZBI
is one of the most commonly used instruments for assess-
ing burden experienced by the caregivers of dementia pa-
tients. To minimize respondent burden, we selected the
ZBI-12, which was found to produce comparable results
to the original version with equal psychometric quality
[46]. Each item can be rated on a five-point scale, with to-
tal scores ranging from 0 to 48. Higher scores suggest
greater caregiver burden.Quality of life will be measured using the Quality of
Life in Alzheimer’s Disease scale (QoL-AD) [47]. The
QoL-AD was found to be a reliable measure for quality
of life in AD patients with an MMSE .10 [48]. We will
assess the self-report version for the participant and the
informant-based version for the study partner. Both consist
of 13 items, rated on a four-point scale. Total scores range
from 13 to 52, with higher scores reflecting better quality
of life.
Finally, we will include an apathy measure, as apathy can
be a predictor of disease severity in AD [49]. We will use the
informant-based version of the Apathy Evaluation Scale
[50], which consists of 18 statements about the participant’s
thoughts, feelings, and activity. Each item is rated on a four-
point scale. Total scores range from 0 to 72, with higher
scores indicating more severe apathy.
2.3.6. Brain atrophy
Brain atrophy will be measured using magnetic reso-
nance imaging (MRI). For each participant, an MRI
without contrast will be acquired at baseline and
12-month follow-up. Scans will be performed on 3 Tesla
scanners. Sequences include 3D T1-weighted imaging,
T2-weighted imaging, and 3D fluid-attenuated inversion re-
covery (FLAIR). To explore changes in brain activity and
functional and structural connectivity in relation to the
CFC, a resting state scan (4D T2-weighted imaging) and
diffusion tensor imaging will be additionally performed
in the UMCG. Scans will be analyzed using visual rating
and quantitative volumetric imaging tools.
2.3.7. Secondary study parameters
Age, gender, education, cultural background, and dis-
ease severity at baseline are secondary study parameters.
We will investigate their influence on the CFC and provide
norms if necessary. Additionally, we will record whether
patients receive any cognitive enhancing treatment during
the study period, to ensure that we can account for this af-
terward.2.4. Procedures
Eligible participants will receive written and oral infor-
mation. After 1–2 weeks, the research team contacts the
potential participant and study partner to determine
whether they are interested to join the study and to answer
any further questions. When both are willing to participate,
baseline and follow-up visit(s) will be scheduled. At the
beginning of the first visit, both the participant and study
partner sign the informed consent form in presence of the
researcher.
Visits take place at either the participants’ home or the
hospital, depending on the participant’s preference, with
the requirement that this should be consistent for each
study visit. In case of testing at home, separate visits
for the MRI scan will be scheduled nearby the baseline
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raters with a background in neuropsychology. To ensure
high quality and consistent application, we will organize
annual rater meetings which include training in all
involved tests.
Each study visit includes a cognitive assessment for the
participant, which consists of the cognitive part of the CFC
followed by the cognitive reference tests. In the meantime,
the study partner completes the functional part of the CFC
and the visit-related questionnaires independently on an
iPad. Following this, the participant completes the VAS
and visit-related disease burden measures on the iPad
with assistance from the rater. Finally, the rater completes
the remaining interview-based measures with the study
partner.2.5. Sample size
For the test–retest study, we will use the minimal recom-
mended sample size of 50 patients and 30 controls [36]. The
sample size for the longitudinal study is based on the objec-
tive of investigating the ability of the CFC to detect changes
over time. Therefore, sample size formulas for linear models
of longitudinal correlated observational data were used [51].
Assuming a power (1 2 b) of 0.80 and a significance level
(a) of 0.05 (two sided), a sample size of 240 patients is suf-
ficient. As we expect a maximum dropout of 20%, we will
initially include 300 participants.2.6. Statistical analyses
We will investigate test–retest reliability of the CFC us-
ing intraclass correlations and apply the Bland-Altman
method to explore systematic bias such as practice effects.
Using baseline data of the longitudinal study, we will
investigate the factor structure of the CFC by confirmatory
factor analysis. The number of factors will be based on pre-
liminary findings on the CC and A-IADL-Q [17,24]. We
will investigate whether the CFC data meet the criteria
for item response theory (IRT) or bifactor modeling.
Subsequently, we will investigate internal consistency
using Cronbach’s alpha or IRT reliability coefficients
when appropriate.
We will relate longitudinal changes on the CFC (as
dependent variable) to changes on the reference measures
of disease progression (as independent variables) using
linear mixed models with random effects. We will calculate
confidence intervals of repeated-measures effect sizes for
the CFC and traditional tests. We expect that changes on
the CFC moderately relate to changes on the traditional tests
but that effect sizes for the CFC are higher than for the tradi-
tional tests. We will investigate the clinical relevance of
changes by linking actual changes to subjective feelings of
change as measured by the VAS. When the data fit an IRT
model, we also use anchor-based bookmarking methods to
determine the minimal important change [36]. Using linearregression analyses, we will evaluate the influence of
possible confounders such as age, gender, and education
and investigate whether norms are necessary. When the
data fit an IRT model, we will use differential item func-
tioning to explore the influence of possible confounders
per item.3. Discussion
Our aim in the Catch-Cog study is to develop and
validate a composite measure combining cognition and
function: the CFC. We expect that the CFC is able to
detect clinically relevant changes over time in MCI and
mild AD. We will investigate this with a test–retest study
followed by a longitudinal construct validation in a multi-
center, prospective cohort. The CFC is based on prepara-
tory work on the CC and A-IADL-Q. The reliability and
validity of these measures have already been demonstrated
in existing cohort data [17,23,24,26]. The present study
goes a step beyond by performing an independent
validation, which is necessary to determine whether the
CFC is suitable for implementation in future cohorts and
clinical trials [28].
Other composite measures are described in the literature.
Recently designed composite measures for detecting cogni-
tive changes in preclinical AD include the theoretical based
ADCS Preclinical Alzheimer Cognitive Composite [40] and
the empirically derived Alzheimer’s Prevention Initiative
composites [30,52]. Although some subtests will be able to
detect decline in later disease stages (i.e., MCI and mild
AD) as well, others will probably show floor effects in
these stages. Existing composite measures for MCI and
mild AD contain tests that have shown to be sensitive in
these stages, and some have also included a functional
component [29–32]. However, they do not focus on
specific IADL functions. We expect the Catch-Cog study
to contribute to this field by designing a composite measure
that integrates (1) sensitive cognitive tests and (2) a measure
focusing on specific daily skills that are vulnerable for
decline in AD. Although there is evidence that cognitive
impairment precedes functional impairment in mild AD
[53], we do not expect that decline on the CFC will be pri-
marily driven by changes on the cognitive tests. In contrast,
we believe that combining our selected cognitive and func-
tional measures may improve statistical power to detect
changes and aid the measurement of clinical progression
in early dementia stages. The Food and Drug Administration
encourages the use of assessment tools that combine cogni-
tive and functional endpoints, if they are properly validated
and have the potential to detect clinically meaningful
changes [54].
An important strength of Catch-Cog is the mixed-
methods approach for developing and validating the
CFC, including the use of input from different stakeholders
(e.g., patients and experts). This will advance the clinical
relevance and acceptability for patients to ease future
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international, multicenter character of the study, which en-
ables us to cross-culturally validate the CFC.
A main challenge for this study is the absence of a gold
standard for “clinical progression.” Furthermore, included
reference tests may show limited sensitivity to changes,
which could be a potential limitation. We aim to obviate
this with a construct validation approach, by involving
different clinical and biological measures related to
disease progression that are less likely to suffer from ceil-
ing effects, such as hippocampal volume. Second, it could
be argued that a follow-up period of 1 year is relatively
short for expecting progression in MCI and mild AD.
However, both the A-IADL-Q and subtests of the CC
have shown to be able to capture changes within the
1-year time frame. We therefore expect the CFC to detect
decline after 1 year as well. We also aim to set up future
research projects that will address a longer follow-up
period for the CFC.
To conclude, we expect Catch-Cog to contribute to the
improvement of longitudinal measurement in early de-
mentia stages of AD. A short and concise composite mea-
sure combining cognition and function will advance the
monitoring of clinical progression as well as the evalua-
tion of treatment effects.Acknowledgments
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1. Systematic review: We searched PubMed for publi-
cations on measurement instruments for clinically
relevant changes over time in mild cognitive impair-
ment (MCI) and mild dementia due to Alzheimer’s
disease (AD).
2. Interpretation: There is an urgent need for a brief,
reliable, valid, and clinically relevant measure,
which is able to detect changes over time in early de-
mentia stages of AD. In the Catch-Cog study, our aim
is to design and validate a composite measure
combining sensitive cognitive and functional tests:
the cognitive-functional composite (CFC). The CFC
is developed based on preparatory work, input from
patients and experts, and test–retest analyses.Wewill
investigate its sensitivity over time by performing a
longitudinal construct validation study in a multi-
center, prospective cohort consisting of subjects with
MCI and mild AD.
3. Future directions: By performing an independent
longitudinal validation, we expect the novel CFC to
contribute to the improvement of disease monitoring
and treatment evaluation.
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